Eisai Co., Ltd. (ESAIY)
OTC PINK OTC PINK Primary Summary
The 3 Best Neuroscience Biotech Stocks to Buy Now
Problems with the central nervous system are the second leading cause of death globally, the World Health Organization determined in 2022. One reason for this situation is that it's extremely difficult to develop effective treatments for these disorders because of the complexity of the CNS, European biotech news website Labiotech reported last year.
The 3 Most Undervalued Pharma Stocks to Buy in June 2024
Pharma stocks have two unique characteristics that can make them great investments for many individuals. First, unlike the vast majority of equities, undervalued pharma stocks can rally even when the economy is performing miserably.
Eisai Co., Ltd. (ESAIY) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Eisai Co., Ltd. ever had a stock split?
Eisai Co., Ltd. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Haruo Naito CEO | OTC PINK Exchange | 28258A107 CUSIP |
| JP Country | 11,067 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Eisai Co., Ltd. is a prominent pharmaceutical company based in Tokyo, Japan, with a rich history dating back to its incorporation in 1941. Originally founded as Nihon Eisai Co., Ltd., the company underwent a name change to Eisai Co., Ltd. in 1955. It has established itself as a leader in the pharmaceutical field through its extensive research and development, manufacturing, and the sale and international trade of pharmaceuticals. Eisai's mission revolves around contributing to the health and welfare of people worldwide by providing innovative and effective medications for various medical conditions.
Products and Services
- Dayvigo
Dayvigo is marketed by Eisai for the treatment of insomnia, aiding individuals who struggle with sleep disorders to achieve a better night's rest.
- Lenvima
An anticancer agent and molecular targeted medicine, Lenvima is used for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma, making it a versatile option in cancer therapy.
- Methycobal
This product is aimed at treating peripheral neuropathy by aiding nerve regeneration and alleviating symptoms of nerve damage.
- Halaven
Halaven is another anticancer agent in Eisai's portfolio, specifically developed for the treatment of breast cancer, highlighting the company's focus on innovative cancer treatments.
- Jyseleca
A janus kinase inhibitor, Jyseleca represents Eisai's foray into the treatment of autoimmune diseases, aiming to provide relief for those suffering from such conditions.
- Elental
This product is a branched-chain amino acid preparation, designed to support patients who require nutritional management in the context of medical conditions.
- Goofice and Movicol
Both products cater to individuals suffering from chronic constipation, offering solutions that promote bowel movements and relieve discomfort.
- Fycompa
As an antiepileptic agent, Fycompa underscores Eisai's commitment to addressing neurological disorders by helping to manage seizures in patients with epilepsy.
- Pariet
Pariet acts as a proton-pump inhibitor, offering relief to those suffering from acid reflux and related conditions by reducing stomach acid production.
- Aricept
Targeted towards the treatment of Alzheimer's disease and dementia with Lewy bodies, Aricept is pivotal in Eisai's neurological portfolio, aimed at improving memory and cognitive function.
- Chocola BB Plus
This vitamin B2 preparation is designed to address deficiencies and support overall health, reflecting Eisai's dedication to preventative care and wellness.
Contact Information
